Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Rethinking furosemide use for infants with bronchopulmonary dysplasia. Pediatr Pulmonol 2020 05;55(5):1100-1103

Date

03/17/2020

Pubmed ID

32176837

DOI

10.1002/ppul.24722

Scopus ID

2-s2.0-85081729340

Abstract

Diuretics are commonly administered to infants with bronchopulmonary dysplasia (BPD) to improve respiratory function despite the absence of prospective data demonstrating long term benefits. While many potentially adverse effects of furosemide are known to clinicians, its direct and indirect impact on multiple pathophysiological processes need to be understood. While furosemide likely has a role in the management of infants with BPD, clinicians are encouraged to recognize these potential complications associated with furosemide administration. Specifically, a deeper understanding of the impact of diuretics on sodium metabolism neurohumoral regulation of cardiopulmonary physiology is required.

Author List

Segar JL

Author

Jeffrey L. Segar MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Bronchopulmonary Dysplasia
Chronic Disease
Furosemide
Hospitalization
Humans
Infant, Newborn
Infant, Premature
Intensive Care Units, Neonatal
Prospective Studies
jenkins-FCD Prod-478 d1509cf07a111124a2d122fd3df854cc0b993c00